Cargando…
Current Progress on Predictive Biomarkers for Response to Immune Checkpoint Inhibitors in Gastric Cancer: How to Maximize the Immunotherapeutic Benefit?
SIMPLE SUMMARY: The landscape of gastric cancer treatment has changed owing to the widespread use of immune checkpoint inhibitors. Only a subset of patients, though, have reaped substantial benefits. One of the crucial issues in current research is seeking efficacious biomarkers to identify favorabl...
Autores principales: | Liu, Yongqing, Hu, Pengbo, Xu, Liang, Zhang, Xiuyuan, Li, Zhou, Li, Yiming, Qiu, Hong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10137150/ https://www.ncbi.nlm.nih.gov/pubmed/37190201 http://dx.doi.org/10.3390/cancers15082273 |
Ejemplares similares
-
Identification of molecular patterns and prognostic models of epithelial–mesenchymal transition- and immune-combined index in the gastric cancer
por: Zhang, Xiuyuan, et al.
Publicado: (2022) -
Immune checkpoint inhibitors for treatment of thymic epithelial tumors: how to maximize benefit and optimize risk?
por: Zhao, Chen, et al.
Publicado: (2019) -
KIF2C is a Biomarker Correlated With Prognosis and Immunosuppressive Microenvironment in Human Tumors
por: Zhang, Xiuyuan, et al.
Publicado: (2022) -
Identification of molecular pattern and prognostic risk model based on ligand-receptor pairs in liver cancer
por: Hu, Pengbo, et al.
Publicado: (2023) -
How to Best Exploit Immunotherapeutics in Advanced Gastric Cancer: Between Biomarkers and Novel Cell-Based Approaches
por: Ghidini, Michele, et al.
Publicado: (2021)